Exicure
XCUR
NASDAQ
IPO2018
about XCUR
Exicure is a clinical-stage biotechnology company that, following a strategic pivot and asset sale, now focuses on developing therapeutics for hematologic diseases, with its lead drug candidate, Burixafor, currently in development for stem cell mobilization in multiple myeloma patients.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $4.87 | $5.45 | $4.87 | $33.97M | 7.53M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.39 | n/a | n/a | 0% | 0% | 0% |